Precision BioSciences, Inc. Unaudited Pro Forma Condensed Consolidated Financial StatementsAsset Purchase Agreement • August 21st, 2023 • Precision Biosciences Inc • Biological products, (no disgnostic substances)
On August 15, 2023, Precision BioSciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Imugene Limited, an Australian corporation (“Imugene Limited”), and its wholly owned subsidiary Imugene (USA) Inc. (“Imugene US”), a Nevada corporation (collectively, “Imugene”). Pursuant to and simultaneously with the execution of the Purchase Agreement, on August 15, 2023 (the “Closing Date”), Imugene US acquired the manufacturing infrastructure to the Company’s CAR T program that uses azer-cel for the potential treatment of relapsed or refractory non-Hodgkin lymphoma, which includes the Company’s MCAT facility, certain contracts of the Company with respect to the MCAT facility and the Company’s azer-cel program, including the lease to the MCAT facility, and related equipment, supplies, azer-cel clinical trial inventory and other assets related to the Company’s CAR T cell therapy platform (the “Acquisition").
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. LICENSE AGREEMENT by and between IMUGENE (USA) INC. and PRECISION...License Agreement • August 21st, 2023 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • New York
This License Agreement (“Agreement”) is entered into as of August 15, 2023 (the “Effective Date”), by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, having an address at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, U.S.A. (“Precision”), and Imugene (USA) Inc., a corporation organized and existing under the laws of Nevada, with its principal business office located at Suite 200, 701 South Carson St, Carson City, Nevada 89701, U.S.A. (“Imugene”). Imugene and Precision are each hereafter referred to individually as a “Party” and together as the “Parties.”
Certain information marked as [***] has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. ASSET PURCHASE AGREEMENT BY AND AMONG PRECISION BIOSCIENCES, INC., IMUGENE...Asset Purchase Agreement • August 21st, 2023 • Precision Biosciences Inc • Biological products, (no disgnostic substances) • New York
Schedule 1.1(a)(ii) GMP AssetsSchedule 1.1(a)(iii) Laboratory AssetsSchedule 1.1(a)(iv) InventorySchedule 1.1(a)(vii) Other Acquired AssetsSchedule 1.1(b)(xvi) Other Excluded AssetsSchedule 1.2(b) Allocation MethodologySchedule 3.4 Buyer CapitalizationSchedule 7.4(a) Target EmployeesSchedule 6.5 GMP Facility UsageSchedule 7.16(b)-1 Seller Knowledge PersonsSchedule 7.16(b)-2 Shared Contracts
